IRF3 and small cell lung carcinoma: The study indicated that the anti-tumor immune responses following DDR targeting were observed to be mediated through the STING–TBK1–IRF3 pathway in SCLC, which stimulated secretion of the chemokines CCL5 and CXCL10 [80].